Day: May 26, 2025

STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety. Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company’s most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled phase 1b/2a clinical study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue...

CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORSReorganization of the Board of Directors Directors’ terms of office reduced to 4 years Appointment of Ms Michèle Lesieur and Mr Eric Drapé as independent directors Reappointment of two directors_________________________________________________________________ Villepinte, May 23rd, 2025  Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, announces, following the Annual General Meeting of May 23, 2025: – The reorganization of its Board of Directors– The reduction of directors’ terms of office to 4 years– The appointment of Michèle Lesieur and Eric Drapé as independent directors– Renewal of the terms of office of Céline Lamort and Marc Massiot. Recomposition of the Board of Directors Guerbet’s...

Invitation to Q1 2025 Presentation 2 June BW Offshore will release its Q1 2025 results on Monday 2 June at 07:30 CEST. A conference call followed by Q&A will be hosted by CEO Marco Beenen and CFO Ståle Andreassen the same day at 09:00 CEST. Conference call information: You can follow the presentation via webcast with supporting slides and a Q&A module, available on:   BW Offshore Limited – Q1 Presentation Webcast Please note that if you follow the webcast via the above URL, you will experience a 30 second delay compared to the main conference call. The web page works best in an updated browser – Chrome is recommended. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The...

Company announcement no. 31 / 2025Schindellegi, Switzerland – 26 May 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share capital. Under the program, the following transactions have been...

LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) — Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the resignation of its Chair. Mr. Ross Haghighat tendered his resignation on May 24th and it was accepted by the Sernova Board. The Board of Directors of Sernova thanks Ross for his service as a trusted leader and sincerely wishes him luck in the future. ABOUT SERNOVA BIOTHERAPEUTICS Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create Bio-hybrid Organs to treat T1D. A Bio-hybrid...

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS CALGARY, Alberta, May 26, 2025 (GLOBE NEWSWIRE) — Questerre Energy Corporation (“Questerre” or the “Company”) (TSX,OSE:QEC) reported on the recent ruling by the Court of Appeal of Quebec related to Bill 21, An Act ending exploration for petroleum and underground reservoirs and production of petroleum and brine (“Bill 21”). A copy of the ruling in French is available online: https://courdappelduquebec.ca/fileadmin/jugements/200-09-010731-245_Arret_2025-05-22.pdf. Michael Binnion, President and Chief Executive Officer of Questerre, commented, “In its ruling, the Court of Appeal recognized the existence of a serious issue with respect to the constitutionality of Bill 21 and reinstated...

Project Credit Facility through AFG Bank Cameroon, along with Option Exercise by Eagle Eye Asset Holdings to Fund Stage One Operations PERTH, Australia, May 25, 2025 (GLOBE NEWSWIRE) — Canyon Resources Limited (ASX: CAY) (‘Canyon’ or the ‘Company’) is pleased to announce that its wholly owned in-country subsidiary, Camalco Cameroon SA (‘Camalco’) has signed a binding agreement with AFG Bank Cameroon (‘AFG Bank CM’) for a medium-term syndicated credit facility of XAF 82,000,000,000 (~US$140M) (‘Credit Facility’). Canyon will use the credit facility for the acquisition of locomotives, wagons, the development of rail, ore transport infrastructure and the port facility for the flagship Minim Martap Bauxite Project (‘Minim Martap’ or ‘the Project’), located in Cameroon. Importantly, the ~US$140 million Credit Facility, along with the...